newsfilter
← Latest News
PR Newswire·

CARsgen Presents First Clinical Data on Its In Vivo CAR-T Product Candidate CT1182

  • CARsgen Therapeutics Holdings Limited announced preliminary clinical data for CT1182, a CD19/CD20-targeting in vivo CAR T-cell product developed on the CARvivo™ platform for relapsed/refractory B-cell non-Hodgkin lymphoma.
  • As of October 31, 2026, the trial enrolled six patients with aggressive lymphoma subtypes across a dose-exploration range of 1.2 × 10⁸ TU to 7.2 × 10⁸ TU.
  • Among six efficacy-evaluable patients, three achieved complete response & two achieved partial response, with all responses ongoing as of the data cut-off date.
  • No treatment-related serious adverse events, dose-limiting toxicities, or infusion-related reactions were observed; only Grade 1 cytokine release syndrome occurred.
  • The safety profile included no biphasic cytokine elevation, no immune effector cell-associated haemophagocytic lymphohistiocytosis-like syndrome, & no immune effector cell-associated neurotoxicity syndrome.
  • Complete B-cell aplasia was observed in all responding patients, suggesting potential applicability to other B-cell related diseases such as autoimmune disorders.
  • The Company plans further dose exploration in subsequent trials to identify the recommended Phase 2 dose & expects to file for a registrational clinical trial in the first half of 2027.
Company
CARsgen Therapeutics
Keywords
CARsgen Therapeutics